Public Health, Precision Medicine, Pharmacogenomics and Cancer

Public Health studies are essential to optimize populations stratified prevention and cancer care that may be under the influence on the ethnogeographic background of each individual. The molecular characterization of the mechanisms associated with the onset of cancer and its role in the response to cancer therapy, optimizing and improving targeted therapy has been an important outcome of recent research. Precision Medicine, Pharmacogenomics and Comparative Personalized Medicine is incorporated in individualized medicine that focuses on how biomolecular factors may influence individual risk to disease and responses to different medications affecting drug efficacy, drug side effects, and adverse events related to drug therapy. The long-term goal of the research being conducted is identifying individuals at disease risk or responders and non-responders to therapy, and thus increase efficacy of prevention and avoid adverse events and optimize drug dose. In this special issue, we welcome submissions of research and review articles on the biomarkers, molecular mechanisms and integrated strategies that contribute for a Precision Public Health under a Comprehensive Comparative Precision Medicine including gene mutational profile, expression levels of miRNAs/mRNAs, gene methylation, immune response, NGS, GWAS, Artificial Inteligence or others. Furthermore, we deeply welcome submissions on the impact of new cancer prevention or therapeutic opportunities as a result of Precision Medicine/Pharmacogenomic biomarkers development as a contribute to Precision Public Health.